

Contents

Preface	xvii
List of Contributors	xix
1 Cancer Biotherapy: Progress in China	1
<i>Zhen-Yu Ding and Yu-Quan Wei</i>	
1.1 Introduction	1
1.2 Immunotherapy	2
1.2.1 Cancer Vaccine	2
1.2.2 Cell Therapy	3
1.2.3 Antibody Therapy	8
1.3 Gene Therapy	11
1.4 Antiangiogenesis Therapy	19
1.5 Targeted Therapy	21
2 Cancer Targeting Gene–Viro–Therapy and Its Promising Future	33
<i>Xin-Yuan Liu, Wen-Lin Huang, Qi-Jun Qian, Wei-Guo Zou, Zi-Lai Zhang, Liang Chu, Kang-Jian Zhang, Li-Li Zhao, Yan-Hong Zhang, Song-Bo Qiu, Zhen-Wei Zhang, Tian Xiao, Jun-Kai Fan, Na Wei, Xin-Ran Liu, Xin Cao, Jin-Fa Gu, Rui-Cheng Wei, Miao Ding, and Shuai Wu</i>	
2.1 Gene Therapy of Cancer	34
2.1.1 Introduction	34
2.2 Replicating Oncolytic Virus on Cancer Therapy	45
2.3 Cancer Targeting Gene–Viro–Therapy (CTGVT)	47
2.3.1 General Description of CTGVT	47
2.4 Modification of CTGVT	55
2.4.1 Cancer Targeting Dual Gene–Viro–Therapy	55
2.4.2 CTGVT with RNAi	63
2.4.3 CTGVT by Killing CSC	64
2.4.4 CTGVT for Tissue-Specific Cancer	67
2.4.5 CTGVT with Cytokine Armed Antibodies	68
2.5 Questions	71
2.6 Conclusion	73

3	Relationship Between Antiproliferative Activities and Class I MHC Surface Expression of Mouse Interferon Proteins on B16-F10 Melanoma Cells	85
	<i>Ronald G. Jubin, Doranelly H. Koltchev, Diane Vy, and Sidney Pestka</i>	
3.1	Introduction	85
3.2	Materials and Methods	87
	3.2.1 AP Assay	87
	3.2.2 MHC I Up-Regulation	87
3.3	Results	88
	3.3.1 AP Activity	88
	3.3.2 MHC I Surface Expression	90
3.4	Discussion	91
4	Mitotic Regulator Hec1 as a Potential Target for Cancer Therapy	97
	<i>Erin M. Goldblatt, Eva Lee and Wen-Hwa Lee</i>	
4.1	Cell Growth and Cancer	98
4.2	Mitotic Regulators as Cancer Therapy Targets	101
4.3	Discovery of Hec1, a Novel Protein in Mitotic Regulation	103
4.4	Development of Hec1 Inhibitors for Cancer Therapeutics	106
4.5	Conclusion	109
5	Advances in Liposome-Based Targeted Gene Therapy of Cancer	113
	<i>Jennifer L. Hsu, Chi-Hong Chao, Xiaoming Xie, and Mien-Chie Hung</i>	
5.1	Introduction	113
5.2	Cationic Liposome-Mediated Nonviral Gene Delivery	114
5.3	Improvement of Therapeutic Efficiency of Liposome-Mediated Gene Therapy	115
	5.3.1 Modifications of Liposome Composition	115
	5.3.2 Combinational Strategy for Liposome-Mediated Gene Therapy	116
5.4	Improvement of Nonviral Gene Expression System	117
	5.4.1 Cancer/Tissue-Specific Promoters	117
	5.4.2 Two-Step Transcription Amplifier Module	120
	5.4.3 VISA Expression Platform	120
5.5	Therapeutic Genes for Cancer Gene Therapy	121
	5.5.1 p53	121
	5.5.2 E1A	122
	5.5.3 Bik	123
	5.5.4 HSV-TK	124
5.6	Conclusion	124
6	Rewiring the Intracellular Signaling Network in Cancer	135
	<i>Jing Liu and Anning Lin</i>	
6.1	Introduction	135
6.2	The JNK Signaling Pathway	136

6.3	The NF- κ B Signaling Pathway	136
6.4	The Negative Crosstalk Between NF- κ B and JNK1 Wires the TNF- α Signaling Circuitry for Cell Survival	137
6.4.1	The TNF- α Signaling Circuitry and Cell Death	137
6.4.2	The Crosstalk Between NF- κ B and JNK Determines TNF- α Cytotoxicity	138
6.4.3	Multiple Mechanisms Are Involved in NF- κ B-Mediated Inhibition of TNF- α -Induced Prolonged JNK Activation	139
6.4.4	Prolonged JNK1 Activation Contributes to TNF- α -Induced Cell Death Through Elimination of Caspase Inhibitor(S)	141
6.5	The Positive Crosstalk Between NF- κ B and JNK1 Wires the UV Signaling Circuitry for Cell Death	142
6.5.1	The UV Signaling Circuitry and Cell Death	142
6.5.2	Augmentation of UV-Induced Rapid and Robust JNK Activation by NF- κ B Promotes UV-Induced Cell Death	142
6.5.3	The “Priming” Model in Which the Preexisting Nuclear RelA/NF- κ B via Induction of PKC δ to Promote UV-Induced Cell Death	143
6.5.4	The RelA-PKC δ Axis May Be Involved in the Assembly of UV-Induced JNK1 Signosome	143
6.5.5	JNK1 Contributes to UV-Induced Cell Death Through Promotion of both Cytoplasmic and Nuclear Death Events	144
6.6	Toward Cell Signaling-Based Cancer Therapy	145
7	Research and Development of Highly Potent Antibody-Based Drug Conjugates and Fusion Proteins for Cancer Therapy	153
	<i>Rong-guang Shao and Yong-su Zhen</i>	
7.1	Introduction	153
7.2	Intact AbDCs	154
7.2.1	mAb–Maytansinoid Drugs	155
7.2.2	mAb–Auristatin Drugs	159
7.2.3	mAb–Eneidyne Drugs	161
7.3	Downsizing ADCs	163
7.3.1	Fragment mAb–Drug Conjugates	164
7.3.2	Engineered Antibody-Based Fusion Proteins	165
7.4	Conclusion	167
8	Cancer Stem Cell	173
	<i>Qiang Liu, Feng-Yan Yu, Wei Tang, Shi-Cheng Su, and Er-Wei Song</i>	
8.1	Introduction	173
8.2	History of CSC	175
8.3	Controversy Over CSC	177
8.4	Origin of CSC	178

8.5	Pivotal Signaling Pathways in CSCs	180
8.5.1	Wnt Pathway	181
8.5.2	Hedgehog Pathway	181
8.5.3	Notch Pathway	182
8.5.4	Pathways Related with Cancer Therapy	182
8.5.5	Other Pathways	183
8.6	CSCs and Metastasis	184
8.6.1	Phenotype of CSCs Related to Metastasis	184
8.6.2	Mechanism of Cancer Metastasis Regulated by Niche	184
8.6.3	CSC and EMT	185
8.6.4	CSC and Angiogenesis	185
8.6.5	Anoikis and Circulating Tumor Cells	186
8.7	Cancer Therapies Targeting CSCs	186
8.7.1	Targeting the Self-Renewal Ability	187
8.7.2	Targeting Survival Pathways	187
8.7.3	Targeting ABC Transporters	188
8.7.4	Targeting Cell Surface Marker and the Interaction with Niche	188
8.8	Future Directions of CSC	188
9	p53: A Target and a Biomarker of Cancer Therapy?	197
	<i>Xin Lu</i>	
9.1	Introduction	197
9.2	Can p53 Act as a Biomarker in Cancer Management and Therapy?	200
9.2.1	p53 Mutation Status and Cancer Management	200
9.2.2	Clinical Implications of Serological Analysis of Auto-Anti-p53 Antibodies	202
9.3	p53-Based Cancer Therapy	203
9.3.1	Increasing Wild-Type p53-Mediated Killing	203
9.3.2	Utilizing Mutant p53 to Induce Cancer Cell Death	204
9.4	What Can We Do to Accelerate p53-Based Cancer Management and Therapy?	207
10	Recombinant Adenoviral-p53 Agent (Gendicine[®]): Quality Control, Mechanism of Action, and Its Use for Treatment of Malignant Tumors	215
	<i>Shu-Yuan Zhang, You-Yong Lu, and Zhao-Hui Peng</i>	
10.1	Introduction	215
10.2	Recombinant Adenoviral-p53 Agent (Trademarked Gendicine)	218
10.2.1	Product Description	218
10.2.2	Quality Control	219
10.3	Mechanisms of Actions	220
10.4	Safety of Gendicine in Clinics	223

10.5	Efficacy of Gendicine in Clinics	224
10.5.1	Gendicine in Combination with Radiation Therapy for Treatment of Nasopharyngeal Carcinoma and HNSCC	224
10.5.2	Gendicine in Combination with Chemotherapy for Treatment of Advanced Cancers	226
10.5.3	Gendicine in Combination with Hyperthermia for Treatment of Advanced Cancers	232
10.6	Overview of Intellectual Property Rights of Recombinant Ad-p53, Methods of Manufacture, and Clinical Applications	233
10.6.1	Four Core Patents Covering Recombinant Ad-p53 Compositions	233
10.6.2	Two Patents for Methods of Recombinant Ad-p53 Manufacture	235
10.6.3	Two Patented Cell Lines for Production of Recombinant Adenoviral Vectors	235
10.6.4	Patents Covering Clinical Use of Recombinant Ad-p53	236
10.7	Summary and Prospective	237
11	Three-Dimensional Tumor Model and T-Lymphocytes Immunotherapy for Cancer	245
	<i>Hua Liu</i>	
11.1	Introduction	245
11.2	Three-Dimensional Tumor Models	246
11.2.1	Anticancer Drug Discovery	250
11.2.2	<i>In Vitro</i> Drug Resistance Test	251
11.2.3	Metastasis Tumor	252
11.2.4	Cancer Stem Cells	252
11.3	3D Tumor Model and T-Lymphocytes Immune Therapy for Cancer	253
11.3.1	New Dimension of Immune Therapy	253
11.3.2	Activation of Immune Cells (Initial Stage)	255
11.3.3	Proliferation of the Effectors (Induced Stage)	256
11.3.4	Biologic Effects Against Tumor (Effective Stage)	256
11.3.5	Clinical Observation	258
11.4	Recent Advances in Cancer Immune Therapy	258
11.4.1	The Tumor Antigens	258
11.4.2	The Immune Effectors	259
11.4.3	The Host Environment	263
11.5	New Strategies for Cancer Therapy Based on Immune Intervention	266
11.5.1	Synergy and Individualized Cancer Treatments	266
11.5.2	Combinatorial Immunotherapy for Cancer	276
11.6	Conclusion	281

12	Advances in Cancer Chemotherapeutic Drug Research in China	287
	<i>Bin Xu, Jian Ding, Kai-Xian Chen, Ze-Hong Miao, He Huang, Hong Liu, and Xiao-Min Luo</i>	
12.1	Introduction of Background of Anticancer Drug Research in China	287
12.2	Natural-Derived Anticancer Agents Developed in China	290
12.2.1	Gengshengmeisu (Actinomycin K, D)	290
12.2.2	Hydroxycamptothecin	292
12.2.3	Homoharringtonine	292
12.2.4	Polysaccharide Preparations	293
12.2.5	Some Meaningful Anticancer Substances from Traditional Chinese Medicine (TCM)	293
12.3	Synthetic Anticancer Drugs	294
12.3.1	Alkylating Agents	294
12.3.2	Metal Anticancer Agents, Antimony-71 (Sb-71), Sb-57, and so forth	298
12.3.3	Other Effective Compounds and Preparations	299
12.4	New Inhibitors of Topoisomerases and Molecular-Targeted Anticancer Agents	300
12.4.1	New Inhibitors of Topoisomerases	300
12.4.2	Molecular-Targeted Anticancer Agents	311
12.5	Recent Work on Design, Synthesis, and Antitumor Evaluation of Several Series of Derivatives	317
12.5.1	N-Substituted-Thiourea Derivatives	317
12.5.2	3,5-Substituted Indolin-2-One Derivatives	321
12.5.3	3-Nitroquinolines	325
12.5.4	Quercetin-3- <i>O</i> -Amino Acid-Esters	328
12.5.5	Triaminotriazine Derivatives	332
12.6	Discussion and Perspectives	338
13	Doxorubicin Cardiotoxicity Revisited: ROS Versus Top2	351
	<i>Yi Lisa Lyu and Leroy F. Liu</i>	
13.1	Doxorubicin Kills Tumor Cells Through Top2 Poisoning	351
13.2	Doxorubicin Causes Unique Tissue Toxicities	355
13.3	Doxorubicin Cardiotoxicity, an ROS Theory	355
13.4	Doxorubicin Cardiotoxicity, a Top2 Twist	356
13.5	Prevention of Doxorubicin Cardiotoxicity by ICRF-187	357
13.5.1	Antagonizing the Formation of Doxorubicin-Induced Top2–DNA Covalent Adducts	359
13.5.2	Top2 β Depletion Through Proteasome-Mediated Degradation	360
13.6	Conclusion	360

14	Biochemistry and Pharmacology of Human ABCC1/MRP1 and Its Role in Detoxification and in Multidrug Resistance of Cancer Chemotherapy	371
	<i>Wei Mo, Jing-Yuan Liu, and Jian-Ting Zhang</i>	
14.1	Introduction	371
14.2	Structure of ABCC1	372
14.3	Monomer Versus Dimer	376
14.4	Regulations of ABCC1 Expression	377
14.5	Biogenesis and Trafficking	378
14.6	Mechanism of Action	380
14.7	Substrates of ABCC1	384
14.8	Inhibitors of ABCC1	386
14.9	Physiologic Functions of ABCC1	389
14.10	ABCC1 in Clinical Drug Resistance	390
14.11	Conclusion and Perspectives	391
15	The Role of Traditional Chinese Medicine in Clinical Oncology	405
	<i>Yan Sun and Jing-Yu Huang</i>	
15.1	Historical Note on the Understanding of Cancer: West and East	405
15.2	Search for Anticancer Agents from Medicinal Plants	407
15.3	Traditional Medicinal Herbs as BRMs	409
15.3.1	Results of Clinical Trials	409
15.3.2	Experimental Studies	412
15.3.3	Long-Term Follow-Up	415
15.4	TCM as Angiogenesis Inhibitors	416
15.4.1	Studies in Esophageal Cancer	416
15.4.2	In Nonsmall Cell Lung Cancer	423
15.4.3	Other TCM Herbs	424
15.5	Future Perspective—Integration of TCM with Modern Medicine Both in Experimental and in Clinical Study	425
16	Effect of Arsenic Trioxide on Acute Promyelocytic Leukemia and Glioma: Experimental Studies, Clinical Applications, and Perspectives	431
	<i>Shi-Guang Zhao, Jin Zhou, Yao-Hua Liu, Li-Gang Wang, and Bao-Feng Yang</i>	
16.1	Historical Perspectives of Arsenic Derivatives in Medicine	431
16.2	Effect of Arsenic Trioxide in APL	432
16.2.1	What Is the Role of Arsenic in Newly Diagnosed APL?	432
16.2.2	Conclusion and Perspectives: Can We Induce a 100% CR Rate in Newly Diagnosed APL?	434

16.3	The Application of Arsenic Trioxide in Glioma	434
16.3.1	Characteristics of Glioma	434
16.3.2	Experimental Studies	437
16.3.3	Clinical Application	441
16.3.4	Perspectives	445
16.4	Experimental Studies and Clinical Applications of As ₂ O ₃ in Harbin Medical University	447
16.5	Conclusions	447
17	Recent Advances in Nasopharyngeal Carcinoma Research and Its Pathogenesis	453
	<i>Yi-Xin Zeng, Wenlin Huang, and Kai-tai Yao</i>	
17.1	Introduction	453
17.2	Molecular Pathogenesis of NPC	454
17.2.1	Genetic Factor and NPC Susceptibility	454
17.2.2	EBV and NPC	457
17.3	Molecular Diagnosis of NPC	462
17.3.1	Discovery of Molecular Biomarker of NPC	462
17.3.2	Application of Molecular Diagnosis in NPC	466
17.4	Advances in the Treatment of NPC	469
17.4.1	Clinical Application of Cytotoxic Therapeutics	469
17.4.2	Targeted Therapy	470
17.4.3	Immunotherapy	472
17.4.4	Gene Therapy	474
17.5	Summary	479
18	Esophageal Carcinoma	493
	<i>Qi-min Zhan, Lu-hua Wang, Yong-mei Song, Yun-wei Ou, Jing Jiang, Jing Fan, Jing-bo Wang, and Jie Shen</i>	
18.1	An Overview of Esophageal Carcinoma	493
18.1.1	Epidemiology	494
18.2	The Pathogenesis of Esophageal Carcinoma	496
18.2.1	The Pathogenesis of Barrett's Esophagus	496
18.2.2	The Pathogenesis of Esophageal Carcinoma	497
18.3	The Etiopathogenesis of Esophageal Carcinoma	503
18.3.1	Diet, Smoking, and Intemperance	503
18.3.2	Genetics and Genes	503
18.3.3	Virus and Inflammation	504
18.4	The Treatment of Esophageal Carcinoma	504
18.4.1	Anatomy	504
18.4.2	Histology	504
18.4.3	Clinical Presentation	505
18.4.4	Diagnostic Work-Up	505
18.4.5	Stage	506
18.4.6	Treatment	507

18.5	The Prevention of Esophageal Carcinomas	521
18.5.1	Protecting the Esophagus by Changing Poor Diet and Living Habits	521
18.5.2	Reducing the Intake of Nitrosamines	522
18.5.3	The Significance of Balanced Nutrition	523
18.5.4	The Active Treatment of Esophageal Epithelial Hyperplasia and Severe Esophagitis	524
18.5.5	The Identification of the Genetic Susceptibility to Esophageal Cancer Among Groups or Individuals	524
19	Research on Colorectal Cancer in China	535
	<i>Shu Zheng, Su-Zhan Zhang, Kun Chen, Yong-Liang Zhu, and Qi Dong</i>	
19.1	The Progress of Epidemiological Study on CRC	535
19.1.1	Introduction	535
19.1.2	Distribution of CRC	536
19.1.3	Environmental Influencing Factors	539
19.1.4	Physical Activity and Obesity	541
19.1.5	Medical History	541
19.1.6	Family History of Cancer	542
19.1.7	Biomarkers	542
19.1.8	Genome Wide Association Study	545
19.1.9	Conclusions	546
19.2	CRC Screening and Early Detection in China	547
19.2.1	Introduction	547
19.2.2	The First Population-Based CRC Screening and Prospective Cohort Study in Haining County	547
19.2.3	Cluster Randomization Trial of Sequence Mass Screening for CRC in Jiashan County	551
19.2.4	Validity of Immunochemical Fecal Occult Blood Test and High-Risk Questionnaire in a Population-Based CRC Screening in Hangzhou	554
19.2.5	Conclusion	555
19.3	The Clue of Microbe Pathogens and CRC—Study on the Carcinogenesis of Microcystin and <i>H. pylori</i>	556
19.3.1	Introduction	556
19.3.2	Epidemiology Survey of Microcystin and <i>H. pylori</i> Prevalence	557
19.3.3	Experimental Study of Molecular Carcinogenesis of Microcystin and <i>H. pylori</i> Molecular Carcinogenesis of Microcystin	558
19.3.4	Molecular Carcinogenesis of <i>H. pylori</i>	561
19.3.5	Activation of Erk1/2 Pathway Was Involved in Carcinogenesis	563
19.3.6	Conclusion	566

19.4	CRC-Related Gene (SNC6/ST13, SNC19/ST14, SNC73)	567
19.4.1	Introduction	567
19.4.2	SNC6/ST13	569
19.4.3	SNC19/ST14	573
19.4.4	SNC73	582
20	Molecular and Cellular Characteristics of Small Cell Lung Cancer: Implications for Molecular-Targeted Cancer Therapy	597
	<i>Yu-Juan Jin, Chao Zheng, and Hong-Bin Ji</i>	
20.1	Introduction	597
20.2	Clinical Diagnosis and Staging of SCLC	598
20.3	The Clinical Management of SCLC	599
20.4	Genetic Alteration of SCLC	600
20.4.1	Oncogenes	600
20.4.2	Allelic Loss of Chromosome in SCLC	601
20.4.3	Dys-regulation of Signaling Pathways in SCLC	603
20.5	Transition from SCLC to Its Variants and/or NSCLC	606
20.6	SCLC Metastasis	607
20.7	Drug Resistance of SCLC	608
20.8	Perspective	609
21	Possibility to Partly Win the War Against Cancer	617
	<i>Xin-Yuan Liu, Guang-Wen Wei, Dong-Qin Yang, Lun-Xu Liu, Lin Ma, Xiao Li, Jian OuYang, Cui-Ping Li, Kang-Jian Zhang, Jian Wang, Liang Chu, Jin-Fa Gu, Huang-Guang Li, Jian Ding, Na Wei, Ying Cai, Xin-Ran Liu, Xin Cao, Yi Chen, Zhi-Jiang Wu, Miao Ding, and Ming Zuo</i>	
21.1	Cancer Targeting Gene-Viro-Therapy with Excellent Antitumor Effects	618
21.1.1	The CTGVT with Potent Antitumor Effect	618
21.1.2	Modification of CTGVT by the Use of Two Genes, CTGVT-DG	618
21.1.3	Other Modification of CTGVT	621
21.2	Super Interferon (sIFN-I) with Super Antitumor Effects on Solid Tumor in Animals and in Patients	622
21.2.1	sINF-I with Super Antitumor Effect on Solid Tumor in Animal Models	624
21.2.2	sIFN-I with Super Antitumor Effects on Solid Tumor in Patients	630
21.2.3	Mechanism of sIFN-I Action	641
21.2.4	Discussion concerning the action of IFN or sIFN-I Briefly	643
21.2.5	Summary of sIFN-I	647
21.3	Cytokine-Induced Killer Cell Therapy and its Important Modification	647
21.3.1	Background	647

21.3.2	Characteristics of CIK Cells	648
21.3.3	Clinical Studies of CIK	648
21.3.4	Modification and Future Prospective of CIK	651
21.3.5	Summary of CIK Therapy	652
21.4	Antibody Protein Therapy and Antibody Gene Therapy or Armed Antibody Gene Therapy	652
21.4.1	Antitumor Protein (mAb) Therapy	652
21.4.2	Immune Therapy Steps Up the Attack	653
21.4.3	Antibody Gene Therapy and Armed Antibody Gene Therapy	653
21.5	Cancer Crusade at 40	654
21.5.1	Introduction: Celebrating an Anniversary (by Paula Kiberstis and Eliot Marshall)	654
21.5.2	Cancer Research and the 90 Billion USD Metaphor (by Eliot Marshall)	655
21.5.3	Combining Target Drug to Stop Resistant Tumors (by Jocelyn Kaiser)	656
21.5.4	Exploring the Genomes of Cancer Cells: Progress and Promise (by M.R. Stratton)	657
21.5.5	A Perspective on Cancer Cell Metastasis (by Christine Chaffer and Robert A. Weinberg)	658
21.5.6	Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion (by R.D. Schreiber, L.J. Old, and M.J. Smyth)	661
21.6	Conclusion	663
	About the Editors	673